The Art of Gene Therapy Digital Summit: EMEA 2021

MilliporeSigma invites you to the Art of Gene Therapy digital summit, a free five-session event drawing on the collective experience of industry leading gene therapy companies and regulatory agencies. The digital summit will shine a light on gene therapy future technologies, technical challenges, lessons learned from scale up to

commercialization and what is on the horizon for regulatory guidelines in addition to a specific focus on the vision for EMEA region specifically. Sign up for all days and have the option to watch the sessions relevant to you. Register today and be at the forefront of the future of gene therapy. This digital summit is co-hosted with PharmaIntelligence.

Register here!

 

Day 1: Monday, May 3rd – The current state of Gene therapy and evolving purification strategies

15:00 – 15:05 Introduction/Opening remarks

Nargisse El Hajjami, Associate Director Cell & Gene Therapy Segment EMEA, MilliporeSigma / Paul Beckett, Technical Applications Consultant Downstream EMEA, MilliporeSigma

15:05 – 16:00 Gene therapy sector overview

Janet Lambert, CEO, Alliance for Regenerative Medicine (ARM)

16:00 – 17:00 Exploring new strategies to improve viral vectors purification processes

Christina Peixoto, Head of Downstream Process ACTU, iBET

 

Day 2: Wednesday, May 5 – The journey from scale up to commercialization

15:00 – 16:00 Yesterday’s learnings: Trial and errors from scale up to commercialization

Susan Abu-Absi, SVP, Pharmaceutical Development & Technology at bluebird bio

16:00 – 17:00 Bottlenecks in viral vector production

Hanna Leinonen, Senior Scientist Upstream, Kuopio Center for Gene and Cell Therapy, KCT / Igor Oruetxebarria, Senior Scientist Downstream, Kuopio Center for Gene and Cell Therapy, KCT

 

Day 3: Monday, May 10 – The future of gene therapy FDA guidelines and analytical development

15:00 – 16:00 Regulatory horizons: 2020 vision on FDA guidelines

Peter Marks, Director of CEBR at FDA

16:00 – 17:00 Tomorrows view: What’s next for analytical development?

Alison Armstrong, Global Head Field Technology Management, Services R&D MilliporeSigma

Day 4: Wednesday, May 12 – Promising technologies of tomorrow and futuristic process design

15:00 – 16:00 Futuristic outlook on gene therapy

Patrick Sullivan, Head of Gene Editing and Novel Modalities R&D MilliporeSigma

16:00 – 17:00 A-Gene: Applying Quality By Design principles to the development and manufacture of gene therapies

Michael Lehmicke, Director of Science and Industry Affairs at ARM

 

Day 5: Monday, May 17 – The next decade of gene therapy in the EMEA region

15:00 – 15:30 Establishing the era of gene therapy in emerging countries – Science and strategy: A case study Shaheer Bardissi, Executive board member, Gene & cell therapy and Immuno-oncology, Minapharm Pharmaceuticals

15:30 – 16:00 Improving access to gene therapies – Focus on EMEA

Lorenzo Montrasio, Human Rights Directorate of the Council of Europe

16:00 – 17:00 The next decade of gene therapy in EMEA: Q&A panel discussion

Ranjeet Patil, Segment Head, Cell and Gene Therapy, MilliporeSigma

Lorenzo Montrasio, Human Rights Directorate of the Council of Europe

Jim McNally’s, Chief Scientific Officer, BioAgilytix

Mazen Hassanain, Managing Director SaudiVax – KSA

Anthony Shillings, Head of Downstream Proceed Development Cell and Gene Therapy, GSK – UK